2013年ACC/AHA胆固醇管理指南在美国心脏病实践中的采纳情况
该研究基于ACC PINNACLE注册登记,分析161家心脏病实践机构在2013年ACC/AHA胆固醇管理指南发布前后(2012年9月1日至2013年11月1日 vs 2014年2月1日至2015年4月1日)中高强度他汀及非他汀类降脂治疗的使用趋势。结果显示,总体队列和动脉粥样硬化性心血管疾病(ASCVD)队列中高强度他汀使用呈上升趋势,但该趋势在指南发布前已存在;其他风险组无显著趋势变化,非他汀类降脂治疗使用未变。结论认为指南采纳程度有限,需及时干预以改善指南一致性实践。
要点
- 在161家心脏病实践机构中,中高强度他汀使用率总体队列从指南前的62.1%升至指南后的66.6%,ASCVD队列从62.7%升至67.0%。
- 分层逻辑回归显示,总体队列和ASCVD队列中高强度他汀使用斜率显著增加(分别为4.8%和4.3%,P均<.01),但该趋势在指南发布前已存在。
- 其他风险组(LDL-C≥190 mg/dL、糖尿病、10年ASCVD风险≥7.5%)中高强度他汀使用趋势无显著变化,非他汀类降脂治疗在所有风险组均未变。
核心结论
- 2013年ACC/AHA胆固醇管理指南在美国心脏病实践中的采纳程度有限,需及时干预以改善指南一致性实践,降低ASCVD负担。
研究设计与样本
- 基于ACC PINNACLE注册登记的间断时间序列分析,纳入161家心脏病实践机构,指南前(2012年9月1日至2013年11月1日)有1 105 356例患者(2 431 192次就诊),指南后(2014年2月1日至2015年4月1日)有1 116 472例患者(2 377 219次就诊)。
- 约97%的患者患有ASCVD,按4个互斥风险组分层,采用分层逻辑回归模型评估中高强度他汀和非他汀类降脂治疗使用趋势的差异。
主要发现
- 中高强度他汀使用率:总体队列指南前62.1% vs 指南后66.6%;ASCVD队列指南前62.7% vs 指南后67.0%;LDL-C≥190 mg/dL队列指南前50.6% vs 指南后52.3%;糖尿病队列指南前52.4% vs 指南后55.2%;10年ASCVD风险≥7.5%的剩余组指南前41.9% vs 指南后46.9%。
- 分层逻辑回归模型中,总体队列中高强度他汀使用显著增加4.8%,ASCVD队列显著增加4.3%(两者斜率P<.01),其他风险队列无显著变化。
- 非他汀类降脂治疗使用在指南前后所有风险组的分层逻辑回归模型中均保持不变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline recommends moderate-intensity to high-intensity statin therapy in eligible patients. OBJECTIVE: To examine adoption of the 2013 ACC/AHA guideline in US cardiology practices. DESIGN, SETTING, AND PARTICIPANTS: Among 161 cardiology practices, trends in the use of moderate-intensity to high-intensity statin and nonstatin lipid-lowering therapy (LLT) were analyzed before (September 1, 2012, to November 1, 2013) and after (February 1, 2014, to April 1, 2015) publication of the 2013 ACC/AHA guideline among 4 mutually exclusive risk groups within the ACC Practice Innovation and Clinical Excellence Registry. Interrupted time series analysis was used to evaluate for differences in trend in use of moderate-intensity to high-intensity statin and nonstatin LLT use in hierarchical logistic regression models. Participants were a population-based sample of 1 105 356 preguideline patients (2 431 192 patient encounters) and 1 116 472 postguideline patients (2 377 219 patient encounters). Approximately 97% of patients had atherosclerotic cardiovascular disease (ASCVD). EXPOSURES: Moderate-intensity to high-intensity statin and nonstatin LLT use before and after publication of the 2013 ACC/AHA guideline. MAIN OUTCOMES AND MEASURES: Time trend in the use of moderate-intensity to high-intensity statin and nonstatin LLT. RESULTS: In the study cohort, the mean (SD) age was 69.6 (12.1) years among 1 105 356 patients (40.2% female) before publication of the guideline and 70.0 (11.9) years among 1 116 472 patients (39.8% female) after publication of the guideline. Although there was a trend toward increasing use of moderate-intensity to high-intensity statins overall and in the ASCVD cohort, such a trend was already present before publication of the guideline. No significant difference in trend in the use of moderate-intensity to high-intensity statins was observed in other groups. The use of moderate-intensity to high-intensity statin therapy was 62.1% (before publication of the guideline) and 66.6% (after publication of the guideline) in the overall cohort, 62.7% (before publication) and 67.0% (after publication) in the ASCVD cohort, 50.6% (before publication) and 52.3% (after publication) in the cohort with elevated low-density lipoprotein cholesterol levels (ie, ≥190 mg/dL), 52.4% (before publication) and 55.2% (after publication) in the diabetes cohort, and 41.9% (before publication) and 46.9% (after publication) in the remaining group with 10-year ASCVD risk of 7.5% or higher. In hierarchical logistic regression models, there was a significant increase in the use of moderate-intensity to high-intensity statins in the overall cohort (4.8%) and in the ASCVD cohort (4.3%) (P < .01 for slope for both). There was no significant change for other risk cohorts. Nonstatin LLT use remained unchanged in the preguideline and postguideline periods in the hierarchical logistic regression models for all of the risk groups. CONCLUSIONS AND RELEVANCE: Adoption of the 2013 ACC/AHA Cholesterol Management Guideline in cardiology practices was modest. Timely interventions are needed to improve guideline-concordant practice to reduce the burden of ASCVD.
引用
- Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017. PMID: 28249067. doi:10.1001/jamacardio.2016.5922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。